Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs
Lotte van der Weijst(European Organisation for Research and Treatment of Cancer), Madeline Pe(KU Leuven), Ahu Alanya(European Organisation for Research and Treatment of Cancer), Kathy Oliver(European CanCer Organisation), Katarzyna Wac(University of Geneva), Vesna Bjelic‐Radisic(Medical University of Graz), Susanne Singer(Jagiellonian University), Jolie Ringash(University Health Network), Galina Velikova(Leeds Teaching Hospitals NHS Trust), John Ramage(Basingstoke and North Hampshire Hospital), Abigirl Machingura(European Organisation for Research and Treatment of Cancer), Winette T.A. van der Graaf(Radboud University Medical Center), Heike Schmidt(Jagiellonian University), Olga Husson(The Netherlands Cancer Institute), Lisa M. Wintner(Universität Innsbruck), Hans‐Henning Flechtner(Jagiellonian University), Roger Wilson(Advocates for Youth), Michael Koller(University Hospital Regensburg), Jens Lehmann(Universität Innsbruck), Renée Bultijnck(Ghent University), Kathy Taylor(Johannes Gutenberg University Mainz), Lúcia P C Senna(European Organisation for Research and Treatment of Cancer), Emma Lidington(Queen Mary University of London)
Cited by 16
Related Papers
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
|JNCI Journal of the National Cancer Institute|1993|15.9k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
|Journal of Clinical Oncology|2013|830